Patent ID: 8449910

Claim:
A pharmaceutical composition comprising: from 750 mg to 850 mg ibuprofen as an active pharmaceutical ingredient and from 24 mg to 28 mg famotidine as an active pharmaceutical ingredient, wherein the pharmaceutical composition is in the form of a bilayer tablet, wherein the ibuprofen active pharmaceutical ingredient is present in a first layer and the famotidine active pharmaceutical ingredient is present in a second layer that is in direct contact with the first layer, wherein at least one binder is present in the first layer and/or the second layer, wherein the pharmaceutical composition is formulated for immediate release, and wherein none of the composition, the first layer, the second layer, the famotidine active pharmaceutical ingredient, or the ibuprofen active pharmaceutical ingredient is enterically coated or formulated for sustained or delayed release, wherein the pharmaceutical composition is formulated so that release of the ibuprofen active pharmaceutical ingredient and the famotidine active pharmaceutical ingredient begins to occur at about the same time, wherein no more than about 1% of a sulfamide is present when the composition is stored at 40° C. and 75% relative humidity for a period of one month or at least 90% of the amount of ibuprofen initially present and at least 90% of the amount of famotidine initially present remains after the composition is stored at 40° C. and 75% relative humidity for a period of one month, and wherein the famotidine active pharmaceutical ingredient and the ibuprofen active pharmaceutical ingredient have a direct contact that does not exceed 130 mm 2 , provided that the pharmaceutical composition is not a tablet-in-tablet formulation having a famotidine shell completely surrounding an ibuprofen core.